JARID2 和 EZH2，人类癌症中重要的表观遗传学驱动因子。

JARID2 and EZH2, the eminent epigenetic drivers in human cancer.

机构信息

Cancer Biology and Stem Cell Biology Laboratory, Department of Genetic Engineering, SRM Institute of Science and Technology, Kattankulathur, TamilNadu - 603203, India.

出版信息

Gene. 2023 Aug 30;879:147584. doi: 10.1016/j.gene.2023.147584. Epub 2023 Jun 21.

DOI:10.1016/j.gene.2023.147584

PMID:37353042

Abstract

Cancer has become a prominent cause of death, accounting for approximately 10 million deaths worldwide as per the World Health Organization report 2020. Epigenetics deal with the alterations of heritable phenotypes, except for DNA alterations. Currently, we are trying to comprehend the role of utmost significant epigenetic genes involved in the burgeoning of human cancer. A sundry of studies have reported the Enhancer of Zeste Homologue2 (EZH2) as a prime catalytic subunit of Polycomb Repressive Complex2, which is involved in several pivotal activities, including embryogenesis. In addition, EZH2 has detrimental effects leading to the onset and metastasis of several cancers. Jumonji AT Rich Interacting Domain2 (JARID2), an undebated crucial nuclear factor, has strong coordination with the PRC2 family. In this review, we discuss various epigenetic entities, primarily focusing on the possible role and mechanism of EZH2 and the significant contribution of JARID2 in human cancers.

摘要

根据世界卫生组织 2020 年的报告，癌症已成为全球主要的死亡原因，约占全球死亡人数的 1000 万。表观遗传学研究的是除 DNA 改变之外可遗传表型的改变。目前，我们试图了解在人类癌症发生过程中涉及的最重要的表观遗传基因的作用。许多研究报告称，EZH2（ Enhancer of Zeste Homologue2 ）是多梳抑制复合物 2 的主要催化亚基，参与包括胚胎发生在内的几个关键活动。此外，EZH2 还会产生有害影响，导致多种癌症的发生和转移。JARID2（ Jumonji AT Rich Interacting Domain2 ）是一个无争议的关键核因子，与 PRC2 家族有很强的协调作用。在这篇综述中，我们讨论了各种表观遗传实体，主要集中在 EZH2 的可能作用和机制，以及 JARID2 在人类癌症中的重要贡献。